Three of the clinical trials resulting in immunosuppression-associated AEs were studies for hemophilia B gene therapy (however, a different AAV gene therapy was used in each case) and another two were for DMD, while studies for hemophilia A, MPS type IIIB, and SMA presented with immunosuppression-associated AEs in one clinical trial each. The gene discussed is DMD; the disease is hemophilia B.